Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for chronic cough conditions, addressing significant unmet medical needs in patient populations. Founded in 2011, Trevi Therapeutics, Inc. is based in New Haven, US.

The company is dedicated to developing its investigational product, Haduvio, for chronic cough caused by idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Jennifer Good serves as the CEO and founder and has a history of founding other companies. Trevi Therapeutics has raised a total of USD 55. 00 mn, with the latest funding round being a PIPE on May 7, 2019.

The company has successfully completed 8 deals in total. Trevi Therapeutics is focused on the development of its investigational product, Haduvio (oral nalbuphine ER), which targets chronic cough conditions, particularly in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Haduvio operates through a unique mechanism by acting as a kappa agonist and mu antagonist (KAMA), aiming to alleviate the hypersensitivity disorder contributing to chronic cough. Haduvio addresses the physical, psychological, and social challenges faced by patients, which affect up to 10% of adults.

There are currently no approved therapies in the U. S. for these conditions, emphasizing the medical need Trevi aims to fulfill. The company is advancing clinical development, primarily in the U.

S. market, for patients suffering from chronic cough associated with IPF and RCC. Trevi Therapeutics is engaged in clinical trials to advance Haduvio's development, focusing on potential revenue generation following market approval and commercialization of the product. The business model emphasizes direct-to-consumer strategies, especially targeting healthcare providers to prescribe Haduvio.

Revenue generation is expected upon product market entry, with healthcare professionals likely to recommend Haduvio for chronic cough treatment. Pricing strategies will reflect the unique value proposition of Haduvio, aligning with industry standards for similar therapies. Trevi's primary revenue stream is anticipated from the successful sales and distribution of Haduvio after receiving approval in relevant markets. Trevi Therapeutics plans to utilize the proceeds from its recent PIPE funding of USD 55.

00 mn to advance the clinical development of Haduvio and explore potential new products aimed at chronic cough conditions. The company is focused on expanding its reach in the U. S. market, targeting specific patient populations suffering from chronic cough resulting from IPF and RCC.

The company aims to strategically position Haduvio in the healthcare market, enabling its entry by leveraging the recent funding to support clinical trials, regulatory processes, and eventual product launch.